These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6938398)

  • 1. Expiratory ventilatory capacity measurements in children with cystic fibrosis treated by oral acetylcysteine.
    Steil E; Niessen KH
    Eur J Respir Dis Suppl; 1980; 111():132-3. PubMed ID: 6938398
    [No Abstract]   [Full Text] [Related]  

  • 2. The immediate effect of physiotherapy and aerosol treatment on pulmonary function in children with cystic fibrosis.
    Kerrebijn KF; Veentjer R; Bonzet-vd Water E
    Eur J Respir Dis; 1982 Jan; 63(1):35-42. PubMed ID: 7067754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the peak expiratory flow rate in children using a miniaturized flowmeter].
    Grenier B; Bidault C; Demont F; Caurier B
    Ann Pediatr (Paris); 1986 Sep; 33(7):617-21. PubMed ID: 3777771
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral acetylcysteine in cystic fibrosis. A co-operative study.
    Götz M; Kraemer R; Kerrebijn KF; Popow C
    Eur J Respir Dis Suppl; 1980; 111():122-6. PubMed ID: 7011832
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia.
    Stafanger G; Garne S; Howitz P; Morkassel E; Koch C
    Eur Respir J; 1988 Feb; 1(2):161-7. PubMed ID: 3282911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcysteine in the oral mucolytic treatment of cystic fibrosis.
    Stephan U; Böwing B; Goering U; Wiesemann HG; Reinhardt M; Hirche H; Brandt H
    Eur J Respir Dis Suppl; 1980; 111():127-31. PubMed ID: 6938396
    [No Abstract]   [Full Text] [Related]  

  • 7. Transit time analysis of the forced expiratory vital capacity in cystic fibrosis.
    Neuburger N; Levison H; Kruger K
    Am Rev Respir Dis; 1976 Oct; 114(4):753-9. PubMed ID: 970749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Carbocysteine--an effective mucolytic in cystic fibrosis of the lungs].
    Hruskovic I; Brezina M; Kayserová H; Langsádl L; Cervenka J
    Cesk Pediatr; 1988 Oct; 43(10):602-4. PubMed ID: 3208328
    [No Abstract]   [Full Text] [Related]  

  • 9. Area under the maximum expiratory flow-volume curve--a sensitive parameter in the evaluation of airway patency.
    Zapletal A; Hladíková M; Chalupová J; Svobodová T; Vávrová V
    Respiration; 2008; 75(1):40-7. PubMed ID: 17299253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between response to exercise and allergy in patients with cystic fibrosis.
    Zambie MF; Gupta S; Lemen RJ; Hilman B; Waring WW; Sly RM
    Ann Allergy; 1979 May; 42(5):290-4. PubMed ID: 453645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).
    Dietzsch HJ; Gottschalk B; Heyne K; Leupoid W; Wunderlich P
    Pediatrics; 1975 Jan; 55(1):96-100. PubMed ID: 1110869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis.
    Schnabel D; Grasemann C; Staab D; Wollmann H; Ratjen F;
    Pediatrics; 2007 Jun; 119(6):e1230-8. PubMed ID: 17545356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference values and prediction equations for maximal expiratory flow rates in non-smoking normal subjects in Madras.
    Vijayan VK; Rao KV; Venkatesan P; Sankaran K
    Indian J Physiol Pharmacol; 1993 Oct; 37(4):291-7. PubMed ID: 8112804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report.
    Sermet-Gaudelus I; Stoven V; Annereau JP; Witko-Sarsat V; Reinert P; Guyot M; Descamps-Latscha B; Lallemand JY; Lenoir G
    Mediators Inflamm; 1999; 8(1):13-5. PubMed ID: 10704084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The timing of rhDNase in relation to airway clearance therapy-unplugged.
    Tannenbaum EL; Ranganathan S
    Pediatr Pulmonol; 2007 Dec; 42(12):1235; author reply 1236-7. PubMed ID: 17708574
    [No Abstract]   [Full Text] [Related]  

  • 16. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of cystic fibrosis with carbocysteine lysine salt: single-blind comparative study with ambroxol hydrochloride.
    Caramia G; Gagliardini R; Ruffini E; Osimani P; Nobilini A
    J Int Med Res; 1995; 23(4):284-93. PubMed ID: 7589772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Scale of normal values of peak expiratory output in healthy children and adolescents based on flow-volume curves (author's transl)].
    Tessier JF; Gachie JP; Bernadou M; Decourcelles JF; Fréour P
    Rev Fr Mal Respir; 1980; 8(4):297-306. PubMed ID: 7244335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of swimming on forced expiration and sputum clearance in cystic fibrosis.
    Zach MS; Purrer B; Oberwaldner B
    Lancet; 1981 Nov; 2(8257):1201-3. PubMed ID: 6118632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spirometric studies in non-smoking, healthy adults.
    Viljanen AA; Halttunen PK; Kreus KE; Viljanen BC
    Scand J Clin Lab Invest Suppl; 1982; 159():5-20. PubMed ID: 6957974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.